Table 2.
Open in new tab

Detailed Adverse Events and Grades

ReportedGrade 1Grade 2Grade 3Grade 4
QTc prolongation6 (8%)6 (8%)000
Transaminitis4 (5%)3 (4%)1 (1%)00
Elevated CK11 (15%)5 (7%)1 (1%)3 (4%)2 (3%)
Diarrhea4 (5%)4 (5%)000
Any AE19 (25%)12 (16%)1 (1%)4 (5%)2 (3%)
Ivosidenib was dose-reduced0 (0%)
Ivosidenib was discontinued1 (1%)
ReportedGrade 1Grade 2Grade 3Grade 4
QTc prolongation6 (8%)6 (8%)000
Transaminitis4 (5%)3 (4%)1 (1%)00
Elevated CK11 (15%)5 (7%)1 (1%)3 (4%)2 (3%)
Diarrhea4 (5%)4 (5%)000
Any AE19 (25%)12 (16%)1 (1%)4 (5%)2 (3%)
Ivosidenib was dose-reduced0 (0%)
Ivosidenib was discontinued1 (1%)

Abbreviations: AE, adverse event; CK, creatine kinase.

Table 2.
Open in new tab

Detailed Adverse Events and Grades

ReportedGrade 1Grade 2Grade 3Grade 4
QTc prolongation6 (8%)6 (8%)000
Transaminitis4 (5%)3 (4%)1 (1%)00
Elevated CK11 (15%)5 (7%)1 (1%)3 (4%)2 (3%)
Diarrhea4 (5%)4 (5%)000
Any AE19 (25%)12 (16%)1 (1%)4 (5%)2 (3%)
Ivosidenib was dose-reduced0 (0%)
Ivosidenib was discontinued1 (1%)
ReportedGrade 1Grade 2Grade 3Grade 4
QTc prolongation6 (8%)6 (8%)000
Transaminitis4 (5%)3 (4%)1 (1%)00
Elevated CK11 (15%)5 (7%)1 (1%)3 (4%)2 (3%)
Diarrhea4 (5%)4 (5%)000
Any AE19 (25%)12 (16%)1 (1%)4 (5%)2 (3%)
Ivosidenib was dose-reduced0 (0%)
Ivosidenib was discontinued1 (1%)

Abbreviations: AE, adverse event; CK, creatine kinase.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close